Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Novartis announced a collaboration with online learning platform Coursera to offer educational programs to the company’s staff.
AstraZeneca struck a deal to use Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
IFM Therapeutics subsidiary IFM Due and Novartis will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.
Idera Pharmaceuticals announced an immuno-oncology collaboration with AbbVie to evaluate a combination therapy aimed at stimulating the immune system to create an anti-tumor response.
A Chicago-based arbitration panel ruled in favor of Eli Lilly and Company in a claim filed by Adocia S.A. over the companies’ prior collaboration on a rapid-acting insulin.
Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.
Harvard University and Merck launched a collaboration that will provide significant research funding for up to four years to support immuno-oncology research led by Arlene Sharpe, MD, PhD, at Harvard Medical School (HMS).
GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.
Syapse Announces Collaboration with Pfizer in Oncology Precision Medicine Focused on Outcomes Research Using Real-World Evidence
Syapse, which accelerates precision medicine through insights derived from the company’s global health system network, announced a strategic collaboration with Pfizer Inc. to advance cancer outcomes research using real-world evidence toward the ultimate goal of improving patient health.